Palisade Bio Inc. 近日公布了其2026年第一季度的财务业绩,同时着重介绍了其核心候选药物Pali-2108在临床开发方面取得的持续进展。公司管理层在报告中阐述了本季度的运营重点与资金使用情况,并对Pali-2108项目的未来推进计划进行了说明。此次财务与运营更新,旨在向投资者及市场展示公司当前的发展态势与未来的战略方向。
Palisade Bio Inc. 近日公布了其2026年第一季度的财务业绩,同时着重介绍了其核心候选药物Pali-2108在临床开发方面取得的持续进展。公司管理层在报告中阐述了本季度的运营重点与资金使用情况,并对Pali-2108项目的未来推进计划进行了说明。此次财务与运营更新,旨在向投资者及市场展示公司当前的发展态势与未来的战略方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.